By Kate O’Rourke
After a checkered past, gene therapy for hemophilia A and B is finally scoring some clinically meaningful successes, according to leading researchers in the field. Hopes are high that the promising results, most recently seen in Phase I/II trials, will progress to Phase III trials and then the clinic setting.
“The current landscape of gene therapy for hemophilia A and B is quite promising,” said Lindsey George, MD, an attending physician in the Division of